Please assess the completion status of the following clinical trial:

Trial Title: Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal women aged 18 to 70 years experiencing ≥7 moderate to severe hot flashes per day (or ≥50 per week) accompanied by sweating during previous 30 days or longer.~2. Had amenorrhea for ≥12 months, amenorrhea for 6 to 12 months with serum follicle-stimulating hormone (FSH) levels \>40 mIU/mL, or was ≥6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.~3. Willing to discontinue the following: vaginal hormonal products; transdermal or oral estrogen or estrogen/progestin combination; intrauterine progestin; progestin implants; injectable estrogen; topical progesterone cream.~4. Had to have daily average of ≥7 moderate to severe hot flashes and had to complete ≥4 days of diary entries during baseline week to be randomized.~5. If treated with antidepressants, could not have had any changes in drug doses during past month.~Other Inclusions apply.~Exclusion Criteria:~1. Patient treated with a gonadotrophin releasing hormone agonist, anti-estrogens, or aromatase inhibitors within 2 months prior to study entry.~2. Patient treated with estrogen pellets or progestin injectable drugs within 6 months prior to study entry.~3. Patient experience only nighttime hot flashes or worked night shifts on a regular basis.~4. Patient was concurrently treated with gabapentin for other indications. If patient was using gabapentin for treatment of hot flashes, she could be screened after a 7-day washout period provided hot flashes returned.~5. Patient had previously experienced dose-limiting adverse effects that prevented titration of gabapentin to an effective dose.~6. Patient had a hypersensitivity to gabapentin.~7. Patient was in an immunocompromised state.~8. Patient had a malignancy other than basal cell carcinoma within 2 years prior to study entry.~9. Patient had gastric reduction surgery, severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome, uncontrolled inflammatory bowel disease, or unexplained weight loss.~10. Patient had clinically significant abnormal chemistry or hematology results, or calculated glomerular filtration rate \<60 mL/min.~11. Patient had history of substance abuse within year prior to study entry.~12. Patient was concurrently taking morphine.~13. Patient had history of chronic hepatitis B or C, hepatitis within 3 months prior to study entry, or history of human immunodeficiency virus.~Other Exclusions apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- G-ER 1200 mg (Type: EXPERIMENTAL): Gabapentin extended-release (G-ER) 1200 mg
- G-ER 1800 mg (Type: EXPERIMENTAL): Gabapentin extended-release (G-ER) 1800 mg
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo 1200 mg or 1800 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete